Search

A 1-day old boy developed necrotising enterocolitis (NEC) while being treated with ampicillin, gentamicin, meropenem, and vancomycin as empiric antibiotic therapy. The boy showed symptoms such as a bloated abdomen, absent bowel sounds, and elevated inflammatory markers. After a series of medical interventions, including surgery to remove necrotic tissue, the boy was diagnosed with NEC and transferred to another department for further treatment of short bowel syndrome. It was concluded that the NEC was a result of the antibiotics administered. [Extracted from the article]

Subsequently, the patient developed intracerebral haemorrhage secondary to warfarin. Thereafter, the patient died due to intracerebral haemorrhage. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a retrospective cohort study involving adult patients on long-term home parenteral nutrition (HPN) managed at a university hospital (2004-2015), et al. patient [ I age and sex not stated i ] was described, who developed intracerebral haemorrhage during anticoagulant treatment with warfarin [ I route, dosage, duration of treatment to reaction onset and outcome not stated i ]. [Extracted from the article]

She was receiving treatment with levothyroxine-sodium[levothyroxine] 2.8 g/kg daily for hypothyroidism. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 66-year-old woman developed abdominal cramps during treatment with teduglutide for short bowel syndrome. Additionally, she developed iatrogenic hyperthyroidism during treatment with levothyroxine-sodium for hypothyroidism [ I dosages, routes, duration of treatment to reaction onset and outcomes not stated i ]. [Extracted from the article]

On hospitalisation, a CT scan showed a complex mass in the lower abdomen and pelvis, with a fluid attenuating centre encasing small bowel and had spread anteriorly into the abdominal wall. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 44-year-old woman developed invasive abdominal squamous cell carcinoma (SCC) during immunosuppressive treatment with azathioprine for Crohn's disease (CD) The woman, who had a history of longstanding ileocolonic penetrating CD, had undergone multiple small bowel resections and had been receiving home parenteral-nutrition [total parenteral nutrition] for short gut syndrome. SQUAMOUS CELL CARCINOMA (SCC) in A PATIENT with FISTULIZING CROHN'S DISEASE (CD): AN UNUSUAL CAUSE for HYPERCALCEMIA. [Extracted from the article]

Patient 4 from table 2 of the article: A 17-year-old boy, who had de novo autoimmune hepatitis, hepatic artery thrombosis and biliary atresia, underwent three liver transplantations. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a retrospective study involving 786 patients performed at UCLA Mattel Children's Hospital, USA between January 1993 and May 2018, seven patients (3 girls and 4 boys) aged 4-17 years were described, who developed de novo lupus-like glomerulonephritis (DNLLGN) following treatment with tacrolimus or ciclosporin as immunosuppressive therapy [ I routes, dosages and duration of treatments to reactions onsets not stated i ]. Patient 7 from table 2 of the article: A 6-year-old boy, who had psoriasis, gastroschisis, short gut syndrome, prematurity, intestinal failure and asocial liver disease, underwent liver and small bowel transplantations. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event * Drug interaction A girl [ I exact age the reaction onset not stated i ] developed gastrointestinal (GI) intolerance and recurrent pancreatitis during treatment with zidovudine, lamivudine, abacavir, stavudine, didanosine and tenofovir disoproxil fumarate for perinatally acquired HIV infection. By the age of 11.4 years, she was admitted to the hospital five times for GI intolerance and recurrent pancreatitis, which was primarily attributed to the zidovudine, lamivudine, abacavir, stavudine and didanosine therapy. The girl had perinatally acquired HIV infection (diagnosed at the age of 3 months), short gut syndrome, spastic paraplegia, seizure disorder, dependence for unspecified medications and dependence on total parenteral nutrition. [Extracted from the article]

Use of lactase enzyme for control of diarrhea in patients breast fed with short bowel syndrome. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a report of two patients, a male neonate [ I exact age not stated i ; patient 1] was described, who exhibited lack of efficacy during treatment with racecadotril and loperamide for diarrhoea. He experienced lack of efficacy during treatment with racecadotril and loperamide for diarrhoea. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 26-year-old woman experienced hyperammonaemic encephalopathy exacerbation during treatment with parenteral nutrition supplements. She became progressively encephalopathic, and her ammonia levels elevated despite treatment with lactulose and rifaximin [ I duration of treatment to reaction onset not stated i ]. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 65-year-old woman developed worsening of D-lactic acidosis during treatment with Ringer's lactate. Based on the investigations, she was found to have D-lactic acidosis, which was further worsened due to administration of Ringer's lactate [ I time to reaction onset not stated i ]. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 74-year-old woman exhibited lack of efficacy while receiving colestyramine, loperamide, octreotide, pantoprazole and plantago ovata for high output ostomy with short bowel syndrome. Her short bowel syndrome and height output ostomy was treated with serial addition of loperamide, plantago ovata [ I Psyllium i ], cholestyramine, pantoprazole [Protonix] and octreotide [ I dosages and routes not stated i ]. Thus, tincture of opium was added to her treatment regimen, which reduced her ostomy output to 400cc daily. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 62-year-old woman developed polypoid lesions while receiving treatment with teduglutide for small bowel Crohn's disease. The woman with a Crohn's disease and rectal cancer was admitted with polypoid lesions on her colostomy at the age of 62 years. Her medical history was significant for small bowel Crohn's disease, which required multiple resections. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event * Drug interaction A 66-year-old man developed small bowel necrosis following concomitant use of sevelamer for hyperphosphataemia and sodium polystyrene sulfonate for hyperkalaemia [ I routes not stated i ]. The bowel resection specimen revealed acute ischaemic enteritis featuring mucosal ulceration associated with crystals morphologically compatible with sevelamer and sodium polystyrene sulfonate, acute organising serositis, submucosal arterial and venous thrombosis. SMALL BOWEL NECROSIS ASSOCIATED WITH A SINGLE DOSE KAYEXALATE TREATMENT IN A PATIENT WITH CHRONIC SEVELAMER THERAPY. [Extracted from the article]

Two new medicines accepted by the Scottish Medicines Consortium (SMC) are the first through the new ultra-orphan pathway for extremely rare conditions. A similar interim acceptance was granted to three drugs through the SMC's Patient and Clinician Engagement process (for end of life and very rare conditions), subject to ongoing evaluation. [Extracted from the article]

The patients, who had Crohn's disease with short bowel syndrome, started receiving teduglutide injection at a dose of 1.3mg-5mg daily. However, the patients developed weight loss (n=1), cholecystitis (n=1), small bowel obstruction (n=1), nausea (n=1) and obstructive symptoms including vomiting, nausea and abdominal pain (n=1) secondary to teduglutide [ I time to reactions onsets not stated i ]. The patient, who had cholecystitis, the teduglutide dose was tapered on the request of the patient. [Extracted from the article]

A retrospective review of 62 patients from a prospectively filled database described 2 male patients (aged approximately 8 years and 12 years) and one female patient [ I age not stated i ], who developed upper respiratory tract infection, injection site bruises, pharyngitis, epigastric pain, abdominal pain or dark colour of urine during treatment with teduglutide for short bowel syndrome. The patients, who had short bowel syndrome, were chronically parenteral nutritional dependent. The patients developed various adverse effects including upper respiratory tract infection and injection site bruises (n=1), pharyngitis, epigastric pain and injection site bruises (n=1) or dark colour of urine and abdominal pain (n=1) [ I durations of treatment to reactions onset and outcomes not stated i ]. [Extracted from the article]

A male child [ I exact age at reactions onsets not stated i ] developed anti-infliximab antibodies, rash and fever during treatment with infliximab for anastomotic and staple line ulcers with recurrent gastrointestinal (GI) bleeding. He underwent massive small bowel resection; however, he re-developed ulcers and the GI bleeding. B Author comment: b I "At infusion #6, anti-[Infliximab] antibodies were 70AU/mL, the child developed a rash and fever during the infusion and [Infliximab] was stopped." i. [Extracted from the article]

Australians with short bowel syndrome, which can occur following resection of the small intestine, will be able to buy a newly subsidised treatment listed on the Pharmaceutical Benefits Scheme (PBS) from 1 October. Another change to the PBS on the same date is the extension of Dysport (clostridium Botulinum Type A Toxin - Haemagglutinin C Complex) to include patients with spasticity of the upper limbs that is moderate to severe, after an acute event. [Extracted from the article]

The article discusses the U.S. court case wherein hedge fund manager Kyle Bass filed a lawsuit against pharmaceutical firm Shire PLC for its patent on the Gattex short bowel syndrome drug which is allegedly invalied. A background of the case is provided wherein the Patent Trial Appeals Board (PTAB) issued several final decisions which favor Bass. Also explored are the factors affecting PTAB's decision.

The article describes the case of a 70-year-old woman who showed elevated lipase and amylase levels following treatment with teduglutide for short bowel syndrome.

The article describes the case of a 57-year-old woman who developed abdominal pain during treatment with octreotide for high ileostomy output due to short bowel syndrome.

The article presents a case study of a man in his late 30s who experienced abdominal pain during treatment with teduglutide for short bowel syndrome.

An abstract of the article "Clinical Management of Patients with Parenteral Nutrition- Dependent Short Bowel Syndrome during Teduglutide Therapy" by C. Compher and others is presented.

An abstract of the article "A patient with parenteral nutrition-dependent short bowel syndrome and cardiovascular disease with 4-year exposure to teduglutide," by C. Compher and colleagues is presented.